Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck

Review decision - June 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 63 KB)

TA145 Head and neck cancer - cetuximab: review proposal - April 2011 information

Appendix A: provisional matrix of stakeholders (PDF 42 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 91 KB)

NICE issues guidance on the use of cetuximab for the treatment of head and neck cancer (PDF 36 KB)

Head and neck cancer - cetuximab: appeal information

Appeal statement information

Head and neck cancer - cetuximab: Appeal documents

Merck Serono

Appeals received (PDF 75 KB)

Initial scrutiny letter (PDF 31 KB)

Mouth Cancer Foundation

Appeals received (PDF 19 KB)

Initial scrutiny letter (PDF 30 KB)

Royal College of Radiologists

Appeals received (PDF 49 KB)

Initial scrutiny letter (PDF 30 KB)

Head and neck cancer - cetuximab: Result of Appeal (PDF 70 KB)

Head and neck cancer - cetuximab: final appraisal determination information

Head and neck cancer - cetuximab: final appraisal determination (PDF 85 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 44 KB)

Consultee and commentator comments on the ACD

British Association of Head and Neck Oncologists (PDF 13 KB)

Welsh Association of Head and Neck Oncologists (PDF 12 KB)

Royal College of Pathologists (PDF 39 KB)

Royal College of Nursing (PDF 19 KB)

National Association of Laryngectomee Clubs (PDF 685 KB)

Lets Face It (PDF 12 KB)

Merck Serono Ltd (PDF 497 KB)

Dr Nick Slevin (PDF 13 KB)

Head and neck cancer - cetuximab (appraisal consultation)

Head and neck cancer - cetuximab: appraisal consultation document information

Evaluation report

Response from Merck (PDF 273 KB)

Non-manufacturer submissions

Joint submission from NCRI Head & Neck Clinical Studies Group, Royal College of Physicians, Royal College of Radiologists, Joint Collegiate for Oncology and Association of Cancer Physicians. (PDF 45 KB)

British Association of Head and Neck Oncologists (PDF 15 KB)

Letter to Merck requesting extra information following appeal decision (PDF 29 KB)

Slevin (PDF 14 KB)

Letter to consultees and commentators requesting extra information following appeal decision (PDF 17 KB)

Appeal Decision (PDF 70 KB)

Final Appraisal Determination (PDF 75 KB)

Head and neck cancer - cetuximab: Final appraisal determination information

Head and neck cancer - cetuximab: Final appraisal determination (PDF 78 KB)

Response to consultee, commentator and public comments on the ACD (PDF 327 KB)

Head and neck cancer: Final appraisal determination - Nick Slevin (PDF 41 KB)

Expert comments on the ACD

Head and neck cancer: Final appraisal determination - Let's face it (PDF 16 KB)

Head and neck cancer: Final appraisal determination - Merck Pharmaceuticals (PDF 169 KB)

Head and neck cance: Final appraisal determination - Royal College Nursing (PDF 22 KB)

Head and neck cancer: Final appraisal determination - Royal College of Pathologists (PDF 43 KB)

Head and neck cancer: Final appraisal determination - British Association of Head and Neck Oncologists (PDF 20 KB)

Head and neck cancer: Final appraisal determination - King's College Hospital Maxilliofacial Unit - The Head and Neck Oncology Group (PDF 23 KB)

Head and neck cancer - cetuximab: appraisal consultation document information

Evidence considered

Additional evidence considered

EPAR report (PDF 696 KB)

Clinical Expert Written Statement on EPAR report (PDF 17 KB)

Manufacturer submission

Manufacturer submission (PDF 835 KB)

Technical appendix 1 Economics model variables (PDF 177 KB)

Technical appendix 2 (PDF 82 KB)

Technical appendix 3 (PDF 491 KB)

Expert written personal statements

Brady (PDF 42 KB)

Fraser (PDF 50 KB)

Harrington (PDF 40 KB)

Slevin (PDF 2.06 MB)

Pre meeting briefing (PDF 60 KB)

Head and neck cancer - cetuximab: evidence Review Group report (PDF 472 KB)

Update to Consultees and Commentators (PDF 26 KB)

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder information